Pendulum Therapeutics is a biotechnology company improving health through products targeting the microbiome.
Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 9, 2023 | Series Unknown | — | — | — | — | Detail |
Apr 7, 2021 | Series C | $54M | 4 |
![]() |
— | Detail |
May 30, 2019 | Series B | $35M | 5 |
![]() |
— | Detail |
Jun 27, 2017 | Series A | $18.50M | 3 |
![]() ![]() ![]() |
— | Detail |
Jan 1, 2016 | Grant | — | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Series C |
![]() |
Yes | Series A |
![]() |
— | Series C |
![]() |
— | Series C |
![]() |
— | Series C |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Seed |